Sino Biopharma says breast cancer drug approved to manufacture

Business | 11 Feb 2020 2:50 pm

Sino Biopharmaceutical (1177) announced that its “Fulvestrant Injection,” a drug used for the treatment of breast cancer and developed by subsidiary Chia Tai Tianqing Pharmaceutical, has got the approval of abbreviated new drug application from the United States Food and Drug Administration and the marketing authorization issued by the Bundesinstitut für Arzneimittel und Medizinprodukte of Germany, respectively.

Shares in the company gained by 3.2 percent to HK$11.62 as of 1:30 pm.

Search Archive

Advanced Search
February 2020
S M T W T F S

Today's Standard



Yearly Magazine

Yearly Magazine